Opioids are painkillers

The argument

The category of opioids includes both opiates, which are psychoactive drugs derived from opium, and a range of synthetic and non-synthetic drugs with pain-relieving effects. Many pharmaceutical opioids were developed as alternatives to morphine, a highly addictive pain medication with many potential adverse effects — an effort to retain the pain relief while shedding what comes with it. The mechanism explains why that effort has proved difficult. Opioids including morphine are effective as painkillers because they can activate mu and delta opioid receptors, which when activated can block pain signals sent through the nervous system to the brain. This is worth noting for what it does not involve: the drug does not act on the injury or on whatever is generating the pain. It acts on the transmission of the signal, interrupting the message rather than the cause, which is why relief is possible even where nothing about the underlying condition has changed. That same mode of action is what makes these drugs depressants in the broader sense. Their effect is to slow and dampen the signalling activity of the nervous system rather than to stimulate it, and the receptors they work through are not confined to pain pathways. This is where the difficulty arises. Opioid receptors are abundant in areas of the brain where responses to psychoactive substances occur, including the dopamine reward pathway. A drug that relieves pain by binding to these receptors therefore engages the reward system at the same time and by the same means, so the two effects cannot be separated by adjusting the dose. Consequently, opioid use is both psychologically and biochemically addictive and can have a wide range of long-term effects on mental function, such as changes to learning, reward, and stress responses.

Premises

Counter-arguments

Pharmacologically, opioids are usually classified in their own category — analgesics or narcotics — rather than as classic central-nervous-system depressants like alcohol or benzodiazepines. Their principal action is receptor-mediated blockade of pain signalling together with euphoria via the reward pathway, and at therapeutic doses they need not broadly 'slow' the nervous system the way sedatives do. Grouping them under 'depressants' does capture their dangerous respiratory depression at overdose, but it blurs a genuine distinction: opioid pain blockade is a different mechanism from the GABAergic slowing that defines the depressant class.

Rejecting the premises

[Rejecting P1] Activating opioid receptors to block pain is a distinct mechanism from the general CNS slowing that defines depressant drugs; pain blockade is not the same as sedation. [Rejecting P2] Opioids stimulate the dopamine reward pathway (euphoria) as much as they depress, so describing their net effect simply as 'slowing' is incomplete; their signature lethal effect is respiratory depression at overdose, not uniform nervous-system slowing at analgesic doses.